MO-IPS suppresses acute myeloid leukemia through metabolic reprogramming and synergizes with anti-PD-1 immunotherapy.

Authors

Yingwen Wang, Wenjun Zhao, Yanrui Jin, Chen Hu, Xingqi Fang, Shuhong Dong, Baolai Zhang

Published in

Functional & integrative genomics. Volume 26. Issue 1. Jun 17, 2026. Epub Jun 17, 2026.

Abstract

Our prior research identified MO-IPS as a potent MYC-PRMT inhibitor. Here, we re-evaluated its efficacy at optimized lower doses to explore a wider therapeutic window. MO-IPS retained robust anti-proliferative activity in vitro at reduced exposures. In MV-4-11 xenografts, the higher established dose suppressed tumor growth by 72.3% and enabled metabolomic profiling. This revealed a sequential mechanism: rapid MYC suppression followed by delayed downregulation of metabolic enzymes, inducing concurrent disruption of heme biosynthesis and NAD⁺ metabolism. Molecular docking predicted potential binding to UPP1, GAMT, and IDO2, and we observed that MO-IPS downregulates their expression at mRNA and protein levels. Critically, in an immunocompetent C1498 model, a lower, therapeutically relevant dose of MO-IPS (20 mg/kg), titrated to minimize direct cytotoxicity, synergized with PD-1 therapy achieving 68.1% tumor inhibition. Mechanistically, the combination enhanced CD8⁺ T cell infiltration and reduced Treg accumulation, leading to an elevated CD8/Foxp3 ratio. This pivotal finding demonstrates that at reduced exposure, MO-IPS's anti-leukemic efficacy is driven not by overt cytotoxicity but by metabolic reprogramming that establishes a pro-immunogenic tumor microenvironment. Collectively, our work repositions MO-IPS from a cytotoxic MYC-PRMT inhibitor to a multifaceted immunometabolic therapeutic. At optimized lower doses, it orchestrates a coordinated disruption of cancer metabolic vulnerabilities and actively augments anti-tumor immunity, presenting a refined and highly promising combinatorial strategy for AML.

PMID:
42307804
Bibliographic data and abstract were imported from PubMed on 17 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.